Advertisement
Advertisement
CORT
Corcept Therapeutics Inc.
123.57
USDSponsored
+0.33
+0.27%
Aug 25, 15:59 UTC -4
Closed
After-Market
123.50
-0.07
-0.06%
CORT Earnings Reports
Positive Surprise Ratio
CORT beat 27 of 43 last estimates.
63%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$343.22M
/$0.65
Implied change from Q2 26 (Revenue/ EPS)
+33.99%
/+80.56%
Implied change from Q3 25 (Revenue/ EPS)
+65.30%
/+306.25%
Corcept Therapeutics Inc. earnings per share and revenue
On Jul 29, 2026, CORT reported earnings of 0.36 USD per share (EPS) for Q2 26, beating the estimate of 0.00 USD, resulting in a 6958.82% surprise. Revenue reached 256.15 million, compared to an expected 226.26 million, with a 13.21% difference. The market reacted with a +27.29% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of 0.65 USD, with revenue projected to reach 343.22 million USD, implying an increase of 80.56% EPS, and increase of 33.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Corcept Therapeutics Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Corcept Therapeutics Inc. reported EPS of $0.36, beating estimates by 6958.82%, and revenue of $256.15M, 13.21% above expectations.
How did the market react to Corcept Therapeutics Inc.'s Q2 2026 earnings?
The stock price moved up 27.29%, changed from $92.95 before the earnings release to $118.32 the day after.
When is Corcept Therapeutics Inc. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Corcept Therapeutics Inc.'s next earnings report?
Based on 7
analysts, Corcept Therapeutics Inc. is expected to report EPS of $0.65 and revenue of $343.22M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement